The eight patients included in the report demonstrated remarkable survival rates, with one patient in third-line therapy surviving 33 months, significantly surpassing the expected survival of 5.8 months for heavily pre-treated populations. Additionally, four patients in second-line therapy exhibited survival rates over 30 months, compared to the documented OS of 10.5 months for standard treatments. All patients had previously failed treatment with checkpoint inhibitors, indicating the potential of ateganosine as a viable option for those who have exhausted other therapies.
Dr. Vlad Vitoc, CEO of MAIA, expressed optimism regarding these findings, stating, "It’s very encouraging to see such outstanding survival from these patients extending beyond our 24-month trial protocol and without any subsequent treatment. OS surpassing two years bodes well as we continue to monitor patients in our ongoing Phase 3 pivotal trial and in THIO-101 Part C. These results illuminate ateganosine’s valuable role in targeting telomeres to eliminate NSCLC tumor cells and support this treatment as a potential breakthrough therapeutic option for NSCLC."
The ongoing Phase 2 trial has treated 79 patients, with Part C currently enrolling up to 48 participants in Asia and Europe. The promising safety profile of ateganosine, combined with its sequential treatment with cemiplimab, positions it as a potential game-changer in the treatment landscape for NSCLC patients who have not responded to existing therapies. As the trial progresses, further data will be crucial in determining the long-term efficacy and safety of this innovative treatment approach.
